|Bid||198.00 x 800|
|Ask||199.00 x 1300|
|Day's Range||194.51 - 204.84|
|52 Week Range||54.21 - 227.71|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||133.51|
|Earnings Date||Aug 03, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||181.17|
(Bloomberg) -- The U.S. sent 2.5 million doses of Moderna Inc.’s vaccine to Taiwan, reflecting part of President Joe Biden’s pledge to donate 25 million shots worldwide to stem the pandemic. Amid a spike in cases over the past six weeks, Taiwan still faces a serious shortage of vaccines.Brazil reached 500,000 deaths from Covid-19 on Saturday, a toll second only to the U.S. As the milestone was officially passed, thousands protested in major cities against President Jair Bolsonaro and his handlin
When they did -- thanks to Pfizer, BioNTech, and Moderna -- the results were much better than most had hoped for. The Pfizer-BioNTech drug -- now marketed as Comirnaty -- was the first to share phase 3 data. Moderna followed two weeks later with its own impressive results.
It hasn't been a secret that the COVID-19 vaccines developed by Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are highly effective. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss what investors should make of the latest CDC data.